According to the Zhitong Finance APP, Shandong Xinhua Pharmaceutical (000756.SZ) announced that the company recently received approval from the National Medical Products Administration for the transfer of the market authorization holder of the lactulose oral solution (100ml:66.7g), as stated in the 'Drug Supplementary Application Approval Notice'.

The lactulose oral solution (100ml:66.7g) was approved by the National Medical Products Administration in November 2024, with Shandong Xinhua Pharmaceutical becoming the market authorization holder of this product. The market entry of this product will help enrich the company's gastrointestinal drug product line and enhance the overall competitive advantage of the company.